NCT00204672 is a Phase 2/Phase 3 clinical trial of Achipex in Asthma, sponsored by University of Utah.

Who is sponsoring NCT00204672?

NCT00204672 is sponsored by University of Utah.

What drugs are being tested in NCT00204672?

Interventions in NCT00204672: Achipex.

Is NCT00204672 still recruiting?

NCT00204672 is currently completed. Last updated 12 September 2005.

Last reviewed 2005-09-12 · How we verify

NCT00204672

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Role of GER in Exercise Triggered Asthma

Completed Phase 2/Phase 3 Last updated 12 September 2005

What this trial tests

Phase 2/Phase 3 trial testing Achipex in Asthma in 36 participants. Completed in 1 September 2005.

Timeline

1 October 2000

1 September 2005

Quick facts

Lead sponsor	University of Utah
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	diagnostic
Enrollment	36
Start date	1 October 2000
Estimated completion	1 September 2005
Sites	1 location across United States

Drugs / interventions tested

Achipex — full drug profile →

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

University of Utah

Who can join

Adults 18 to 65, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To determine whether patients with exercise-triggered asthma experience GER during exercise.

Sponsor's own description

HYPOTHESIS Gastroesophageal reflux is a major contributor to exercise-triggered asthma. Two groups of patients will be studied: those with asthma who have difficulty with exertion, those without asthma who experience difficulty with exertion. Both groups will experience gastroesophageal reflux (GER) twice of less per week. Patients will complete a treadmill exam to determine their VO2 max. They will then undergo pH monitoring while exercising for 30 minutes at 65-70% of their VO2 max. Subjects will be given placebo or acid suppression pill for 12 weeks. At the end of 12 weeks, the subjects will repeat the exercise (30 minutes) and 24-hour pH study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other University of Utah trials

Trials by the same sponsor.

NCT07515755 — Supplemental Oxygen and Oxygen Desaturations in Colonoscopies · NA · not yet recruiting
NCT07225426 — Personalizing Financial Incentives · NA · recruiting
NCT06716411 — Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness · NA · recruiting
NCT07246538 — Positive Airway Pressure (PAP) System Evaluation in Volunteers · NA · not yet recruiting
NCT04208984 — Diversion Device With Breath Control · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00204672 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Utah
Last refreshed: 12 September 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00204672.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing